[go: up one dir, main page]

SI1853721T1 - Postopek za ugotavljanje odzivnosti na CHK inhibitorje - Google Patents

Postopek za ugotavljanje odzivnosti na CHK inhibitorje

Info

Publication number
SI1853721T1
SI1853721T1 SI200630659T SI200630659T SI1853721T1 SI 1853721 T1 SI1853721 T1 SI 1853721T1 SI 200630659 T SI200630659 T SI 200630659T SI 200630659 T SI200630659 T SI 200630659T SI 1853721 T1 SI1853721 T1 SI 1853721T1
Authority
SI
Slovenia
Prior art keywords
chk1
patient
chk1 inhibitors
determining responsiveness
signal transduction
Prior art date
Application number
SI200630659T
Other languages
English (en)
Inventor
Sonya Zabludoff
Louise Bergeron
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SI1853721T1 publication Critical patent/SI1853721T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200630659T 2005-02-18 2006-02-16 Postopek za ugotavljanje odzivnosti na CHK inhibitorje SI1853721T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65413105P 2005-02-18 2005-02-18
PCT/GB2006/000548 WO2006087557A1 (en) 2005-02-18 2006-02-16 METHOD FOR DETERMINING RESPONSIVENESS TO CHKl INHIBITORS
EP06709785A EP1853721B1 (en) 2005-02-18 2006-02-16 Method for determining responsiveness to chk1 inhibitors

Publications (1)

Publication Number Publication Date
SI1853721T1 true SI1853721T1 (sl) 2010-06-30

Family

ID=36295309

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200630659T SI1853721T1 (sl) 2005-02-18 2006-02-16 Postopek za ugotavljanje odzivnosti na CHK inhibitorje

Country Status (24)

Country Link
US (1) US20080145358A1 (sl)
EP (1) EP1853721B1 (sl)
JP (1) JP2008530575A (sl)
KR (1) KR20070107034A (sl)
CN (1) CN101120096A (sl)
AT (1) ATE464395T1 (sl)
AU (1) AU2006215413B2 (sl)
BR (1) BRPI0607798A2 (sl)
CA (1) CA2598185A1 (sl)
CY (1) CY1110076T1 (sl)
DE (1) DE602006013604D1 (sl)
DK (1) DK1853721T3 (sl)
ES (1) ES2341796T3 (sl)
HK (1) HK1113059A1 (sl)
HR (1) HRP20100313T1 (sl)
IL (1) IL184873A0 (sl)
MX (1) MX2007010073A (sl)
NO (1) NO20074610L (sl)
NZ (1) NZ556718A (sl)
PL (1) PL1853721T3 (sl)
PT (1) PT1853721E (sl)
SI (1) SI1853721T1 (sl)
WO (1) WO2006087557A1 (sl)
ZA (1) ZA200706670B (sl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2086580A2 (en) * 2006-11-21 2009-08-12 Merial Limited Prime boost canine leishmania vaccine
WO2008121766A1 (en) 2007-03-29 2008-10-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Genetic changes in atm and atr/chek1 as prognostic indicators in cancer
US8173366B2 (en) 2007-03-29 2012-05-08 University of Pittsburgh—of the Commonwealth System of Higher Education Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer
GB0720113D0 (en) * 2007-10-15 2007-11-28 Cambridge Cancer Diagnostics L Diagnostic, prognostic and predictive testing for cancer
JP5436786B2 (ja) * 2008-03-06 2014-03-05 オリンパス株式会社 細胞周期計測方法
WO2010076887A1 (en) * 2009-01-05 2010-07-08 Banyu Pharmaceutical Co.,Ltd. Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
WO2016126616A1 (en) 2015-02-02 2016-08-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and kits for measuring and quantifying dna double-stranded breaks using gamma-h2ax and h2ax
JP2019514396A (ja) * 2016-05-05 2019-06-06 ナントミクス,エルエルシー チェックポイント不全およびそれに関する方法
WO2018030547A1 (ja) * 2016-08-12 2018-02-15 日立化成株式会社 血中循環癌細胞の検出方法及び血中循環癌細胞を検出するための前処理方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001161398A (ja) * 1999-12-06 2001-06-19 Igaku Seibutsugaku Kenkyusho:Kk タンパク質リン酸化酵素の活性測定方法およびタンパク質リン酸化酵素の活性測定キット
ES2309484T3 (es) * 2003-01-09 2008-12-16 Pfizer Inc. Derivados de diazepinoindol como inhibidores de quinasa.
BRPI0408256A (pt) * 2003-03-14 2006-03-01 Astrazeneca Ab composto, métodos de tratamento de um humano ou animal, pela limitação da replicação de células, que sofre de cáncer, que sofre de uma doença neoplástica, e que se sofre de doenças proliferativas, uso de um composto, e, processo para a preparação de um composto ou de um seu sal farmaceuticamente aceitável ou de um éster hidrolisável in vivo do mesmo
ES2702942T3 (es) * 2003-04-17 2019-03-06 Alnylam Pharmaceuticals Inc Agentes de ARNi modificados
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.
US20050207998A1 (en) * 2003-07-21 2005-09-22 Yaoping Lu Caffeine salt complexes and methods for using the same in the prevention or treatment of cancer
MXPA06003110A (es) * 2003-09-17 2006-06-20 Icos Corp Uso de inhibidores de chk1 para controlar la proliferacion celular.

Also Published As

Publication number Publication date
DE602006013604D1 (de) 2010-05-27
IL184873A0 (en) 2007-12-03
PL1853721T3 (pl) 2010-08-31
US20080145358A1 (en) 2008-06-19
AU2006215413A1 (en) 2006-08-24
ZA200706670B (en) 2008-10-29
MX2007010073A (es) 2007-10-10
WO2006087557A1 (en) 2006-08-24
AU2006215413B2 (en) 2010-10-07
NO20074610L (no) 2007-11-14
DK1853721T3 (da) 2010-06-14
EP1853721B1 (en) 2010-04-14
CN101120096A (zh) 2008-02-06
NZ556718A (en) 2010-10-29
JP2008530575A (ja) 2008-08-07
PT1853721E (pt) 2010-06-08
EP1853721A1 (en) 2007-11-14
BRPI0607798A2 (pt) 2010-06-22
ES2341796T3 (es) 2010-06-28
CY1110076T1 (el) 2015-01-14
HRP20100313T1 (hr) 2010-07-31
KR20070107034A (ko) 2007-11-06
HK1113059A1 (en) 2008-09-19
ATE464395T1 (de) 2010-04-15
CA2598185A1 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
HK1113059A1 (en) Method for determining responsiveness to chk1 inhibitors
ATE438853T1 (de) Diagnostische testvorrichtung
WO2008131047A3 (en) Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism
WO2008054827A3 (en) Bruton's tyrosine kinase activity probe and method of using
WO2009015233A3 (en) Gefitinib sensitivity-related gene expression and products and methods related thereto
EA200901313A1 (ru) Ингибиторы тирозинкиназы брутона
EP2100899A3 (en) Compounds for proteasome enzyme inhibition
WO2007067968A3 (en) Effects of inhibitors of fgfr3 on gene transcription
WO2008138578A3 (en) Methods, kits, and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
MX2007006640A (es) Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina.
GB0203446D0 (en) Detection and/or monitoring of synuclein-related diseases
WO2008088854A3 (en) Genetic markers for predicting responsiveness to combination therapy
WO2007114986A3 (en) Cooperative probes and methods of using them
ATE511645T1 (de) Testverfahren zum nachweis von antikörpern gegen lysosomenenzyme
WO2008073177A3 (en) Expression profiles associated with irinotecan treatment
EP1692102A4 (en) COMPOSITIONS AND METHODS FOR DETECTING AND TREATING DISEASES AND SUFFERING RELATED TO CHEMOKIN RECEPTORS
FR13C0024I1 (fr) Combinaisons antitumorales contenant vegf-trap et du 5fu ou un de ses derives
EP1893967A4 (en) METHODS AND APPARATUS FOR ENHANCING THE SENSITIVITY OF ZERO CAPILLARY ELECTROPHORESIS
EP1931394A4 (en) APOE4 DOMAIN INTERACTION HEMMER AND APPLICATION METHOD THEREFOR
EP1994172A4 (en) METHOD FOR THE DIAGNOSIS AND / OR PREDICTION OF THE DEVELOPMENT OF ALLERGIC DISEASE AND AGENTS FOR TREATMENT AND / OR PREVENTING THEREOF
WO2008081094A3 (fr) Methode de mesure fonctionnelle de l'activite de la thrombomoduline plasmatique
WO2005113797A3 (en) METHODS FOR DETECTING Lp-PLA2 ACTIVITY AND INHIBITION OF Lp-PLA2 ACTIVITY
ATE333521T1 (de) Detektion von vancomycin-resistenten enterococcus-subspezies
IL181192A0 (en) Method for measuring dynamics of self-assembling systems of biological molecules in vivo and uses for discovering or evaluating therapeutic agents
WO2009140508A3 (en) Methods for predicting a patient's response to egfr inhibitors